Cargando…

Dynamics of anti-RBD (anti-receptor binding domain) levels in diabetes patients following the ChAdOx1 nCoV-19 vaccine (AZD1222) in the Thai population

The ChAdOx1 nCoV-19 vaccine (AZD1222) was used in Thailand during the early outbreak of coronavirus disease 2019 (COVID-19). A previous study showed a low immune response in diabetes patients after the first dose of the AZD1222 vaccine. Furthermore, humoral immune responses after the second vaccinat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sirisreetreerux, Supamas, Porntharukchareon, Thachanun, Dechates, Bothamai, Rangsrisaeneepitak, Vimonsri, Therawit, Phonthip, Worawitchawong, Supanat, Sornsamdang, Gaidganok, Soonklang, Kamonwan, Tawinprai, Kriangkrai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10361991/ https://www.ncbi.nlm.nih.gov/pubmed/37479776 http://dx.doi.org/10.1038/s41598-023-39114-5

Ejemplares similares

Immune Response to CoronaVac and Its Safety in Patients with Type 2 Diabetes Compared with Healthcare Workers
por: Dechates, Bothamai, et al.
Publicado: (2023)

Antibody levels in people with diabetes after one dose of the ChAdOx1 nCoV-19 (AZD1222) vaccine
por: Rangsrisaeneepitak, Vimonsri, et al.
Publicado: (2022)

Persistence of immunogenicity, contributing factors of an immune response, and reactogenicities after a single dose of the ChAdOx1 (AZD1222) COVID-19 vaccine in the Thai population
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

The immunogenicity of the ChAdOx1 nCoV-19 vaccination in participants with underlying comorbidity diseases: A prospective cohort study
por: Porntharukchareon, Thachanun, et al.
Publicado: (2023)

Immunogenicity and safety of an intradermal fractional third dose of ChAdOx1 nCoV-19/AZD1222 vaccine compared with those of a standard intramuscular third dose in volunteers who previously received two doses of CoronaVac: A randomized controlled trial
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
por: Cohen, Guy, et al.
Publicado: (2022)

Immunogenicity and reactogenicity of heterologous prime-boost vaccination with inactivated COVID-19 and ChAdOx1 nCoV-19 (AZD1222) vaccines, a quasi-experimental study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2023)

Safety and Immunogenicity of the BBIBP-CorV Vaccine in Adolescents Aged 12 to 17 Years in the Thai Population: An Immunobridging Study
por: Tawinprai, Kriangkrai, et al.
Publicado: (2022)

Effect of Inactivated SARS-CoV-2 Vaccines and ChAdOx1 nCoV-19 Vaccination to Prevent COVID-19 in Thai Households (VacPrevent trial)
por: Muadchimkaew, Marisa, et al.
Publicado: (2022)

Immunogenicity evaluation of ChAdox1 nCov-19 (AZD1222) vaccine in solid cancer patients in Chulabhorn Hospital
por: Limpawittayakul, Piyarat, et al.
Publicado: (2022)

Role of quantitative hepatitis B surface antigen in predicting inactive carriers and HBsAg seroclearance in HBeAg-negative chronic hepatitis B patients
por: Ungtrakul, Teerapat, et al.
Publicado: (2017)

SARS-CoV-2 seroprevalence among cancer patients and household caregivers in a cancer hospital: Cross-sectional survey after the second COVID-19 wave in Thailand
por: Ungtrakul, Teerapat, et al.
Publicado: (2022)

The clinical outcomes of high neutralizing antibodies titer convalescent plasma therapy in early developed severe COVID-19 patients; a case–control study
por: Nontawong, Nuttakant, et al.
Publicado: (2022)

Immunogenicity of the ChAdOx1 nCoV-19 vaccine in patients with hematologic malignancies
por: Thookhamme, Chayapa, et al.
Publicado: (2023)

Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area
por: Ungtrakul, Teerapat, et al.
Publicado: (2016)

Waning of Anti-spike Antibodies in AZD1222 (ChAdOx1) Vaccinated Healthcare Providers: A Prospective Longitudinal Study
por: Mishra, Sanjeeb K, et al.
Publicado: (2021)

High prevalence of advanced colorectal neoplasia in the Thai population: a prospective screening colonoscopy of 1,404 cases
por: Siripongpreeda, Bunchorn, et al.
Publicado: (2016)

SAT-254 Desmopressin Stimulation Test in a Pregnant Patient with Cushing’s Syndrome
por: Warachit, Wasita, et al.
Publicado: (2020)

Ultrasound screening for cholangiocarcinoma could detect premalignant lesions and early-stage diseases with survival benefits: a population-based prospective study of 4,225 subjects in an endemic area
por: Sungkasubun, Prakongboon, et al.
Publicado: (2016)

Desmopressin Stimulation Test in a Pregnant Patient with Cushing's Disease
por: Parksook, Wasita Warachit, et al.
Publicado: (2021)

Safety after BBIBP-CorV (Sinopharm) COVID-19 Vaccine in Adolescents Aged 10–17 Years in Thailand
por: Thonginnetra, Saraiorn, et al.
Publicado: (2022)

Serum levels of anti-PF4 IgG after AZD1222 (ChAdOx1 nCoV-19) vaccination
por: Cohen, Taylor S., et al.
Publicado: (2022)

SAT-324 An Unusual Association between Pheochromocytoma and Hyperparathyroidism in a Patient with Neurofibromatosis Type 1: A Possible Co-Occurrence of Two Hereditary Endocrine Tumor Syndromes
por: Kiatpanabhikul, Phatharaporn, et al.
Publicado: (2019)

Pembrolizumab- and ipilimumab-induced diabetic ketoacidosis and isolated adrenocorticotropic hormone deficiency: a case report
por: Porntharukchareon, Thachanun, et al.
Publicado: (2020)

Comparison of antibody responses following natural infection with Severe Acute Respiratory Syndrome Coronavirus 2 or receipt of CoronaVac or ChAdOx1 (AZD1222) vaccination in Chiang Mai, Thailand
por: Hongjaisee, Sayamon, et al.
Publicado: (2023)

REATOGENICIDADE COM MEIA DOSE DA VACINA CHADOX1 NCOV-19 (AZD1222)
por: Gouvea, Maria da Penha Gomes, et al.
Publicado: (2022)

The Effect of high temperature on the stability of basal insulin in a pen: a randomized controlled, crossover, equivalence trial
por: Kongmalai, Tanawan, et al.
Publicado: (2022)

High Prevalence of Anti-PF4 Antibodies Following ChAdOx1 nCov-19 (AZD1222) Vaccination Even in the Absence of Thrombotic Events
por: Terpos, Evangelos, et al.
Publicado: (2021)

Safety and Reactogenicity of the ChAdOx1 (AZD1222) COVID-19 Vaccine in Saudi Arabia
por: Al Bahrani, Salma, et al.
Publicado: (2021)

Genomic Analysis of AZD1222 (ChAdOx1) Vaccine Breakthrough Infections in the City of Mumbai
por: Shetty, Arusha, et al.
Publicado: (2022)

Bilateral Adrenal Histoplasmosis
por: Porntharukchareon, Thachanun, et al.
Publicado: (2019)

Calcitonin Changed During Pregnancy in MEN2A With MTC Patient: A Case Report
por: Porntharukchareon, Thachanun, et al.
Publicado: (2021)

Developmental and reproductive safety of AZD1222 (ChAdOx1 nCoV-19) in mice
por: Stebbings, Richard, et al.
Publicado: (2021)

AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in mice
por: Stebbings, Richard, et al.
Publicado: (2022)

Safety and incidence of COVID-19 following ChAdOx1(AZD1222) COVID-19 vaccination in Botswana
por: Shava, Emily, et al.
Publicado: (2023)

Anti-SARS-CoV-2 Neutralizing Antibody Responses after Two Doses of ChAdOx1 nCoV-19 vaccine (AZD1222) in Healthcare Workers
por: Lim, Sera, et al.
Publicado: (2022)

LBODP007 Clinical Characteristics And Treatment Outcomes Of Adrenal Histoplasmosis And Tuberculosis In Thailand: A 15-year Retrospective Study In A Single Tertiary Center
por: Vorasayun, Thanyaporn, et al.
Publicado: (2022)

Fertility rates and birth outcomes after ChAdOx1 nCoV-19 (AZD1222) vaccination
por: Hillson, Kushalinii, et al.
Publicado: (2021)

Geographical distribution of TTS cases following AZD1222 (ChAdOx1 nCoV-19) vaccination
por: Soboleva, Karina, et al.
Publicado: (2022)

An exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
por: Marchevsky, Natalie Gabrielle, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_1oas0m0m3ing56n31ug7lt8let